Rotavirus in New Zealand 2016

Thursday 19th September 2019


Summary

A marked decrease in rotavirus hospitalisations and community infections has occurred in children under 5 years since the oral rotavirus vaccine RotaTeq® was added to the national immunisation schedule on 1 July 2014. This report presents information on rotavirus infections in 2016 from a variety of sources, including national hospital discharges, sentinel hospital-based surveillance and genotyping of rotavirus-positive samples from community and hospital laboratories.

In the two years following the introduction of rotavirus vaccine, there was an 88.7% decrease in the rate of rotavirus hospitalisations for children aged under 5 years compared with the previous five-year average (2010–2014). Socioeconomic disparities remain, with statistically significant higher rotavirus hospitalisation rates in children aged under 5 years in deprivation quintiles 4 and 5, compared with those in quintile 1.

G12P[8] was the predominant (55.4%) rotavirus genotype detected in 2016, and G2P[4] was the second most common (19.1%). Four samples were confirmed as containing a component of the RotaTeq® vaccine, including two from unvaccinated cases.

In July 2017, the rotavirus vaccine on the national immunisation schedule was changed to Rotarix®. Continued rotavirus surveillance will be important to monitor trends in severe rotavirus infection and vaccine selection pressure on rotavirus genotypes.

Note: Click on the document links below to open. These documents are in PDF format. You will need to download the free Adobe Acrobat Reader to view them.

Report:

Rotavirus in New Zealand 2016

 

DOWNLOADS

Rotavirus in New Zealand 2016

Ph: +64 4 914 0700 Fax: +64 4 914 0770 Email: survqueries@esr.cri.nz